- Conditions
- Methamphetamine-Associated Heart Failure, Methamphetamine-Associated Pulmonary Arterial Hypertension
- Interventions
- Increasing control over stimulant use and physical health through incentivized rehabilitation, Usual Care
- Behavioral · Other
- Lead sponsor
- Michael Incze
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
Recruitment Status
Recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
21991
Shown on this page
12
Current sort
Recently updated
Status scope
Recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 829–840 of 21,991 matching trials with status Recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Overweight, Obesity
- Interventions
- Eloralintide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
- Conditions
- Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult, Endometrial Cancer
- Interventions
- TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
- Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 212 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 7 more
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
- Interventions
- LY4052031, Pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 22
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Tobacco Use Disorder, Nicotine Dependence
- Interventions
- Counseling, Contingency management, Text-based support
- Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Colon and Rectal Cancer
- Interventions
- Cemiplimab
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Interventions
- 5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
- Procedure
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 45 Years to 70 Years
- Enrollment
- 9,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2065
- U.S. locations
- 484
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 328 more
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
- Interventions
- Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Interventions
- LY3650150, Placebo, Standard therapy for INCS
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
- Conditions
- Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Interventions
- High-dose Methotrexate
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 7 Years to 22 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
- Conditions
- Opioid Use, Substance Use Disorders, Opioid Analgesia
- Interventions
- Placebo, Oxycodone HCl, Kratom 8g, Kratom 12g, Kratom 16g, Kratom 4g
- Drug
- Lead sponsor
- Christopher D. Verrico
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Medulloblastoma, Medulloblastoma, Non-WNT/Non-SHH
- Interventions
- Digoxin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 15 more